Radiopharmaceuticals regulatory considerations

The EANM is committed to advocating for a regulatory environment that ensures the safe, effective, and timely availability of radiopharmaceuticals across Europe.

EANM / EU & Global Affairs / Policy / Radiopharmaceuticals regulatory considerations

Radiopharmaceuticals regulatory considerations

Radiopharmaceuticals are critical tools in the diagnosis and treatment of a wide range of diseases, from cancer to neurological disorders. Given the unique nature of these medicinal products, radiopharmaceuticals require a regulatory framework that addresses their specific characteristics and challenges. The EANM is committed to advocating for a regulatory environment that ensures the safe, effective, and timely availability of radiopharmaceuticals across Europe.

Main Advocacy Priorities for the EANM

  • Harmonised Regulatory Standards: Advocate for uniform regulatory standards across EU member states to facilitate the seamless approval and distribution of radiopharmaceuticals.
  • Flexible Regulatory Framework: Promote streamlined and flexible processes to reduce delays and enhance patient access to new treatments.  Adaptive regulatory frameworks could quickly respond to technological advancements and emerging scientific knowledge in the field of radiopharmaceuticals.
  • Clear Legal Definitions: Ensure precise legal definitions for radiopharmaceuticals within EU legislation, distinguishing them clearly from other medicinal products. This clarity will help streamline regulatory processes and avoid unnecessary regulatory hurdles.
  • Support for Innovation: Encourage regulatory frameworks that foster innovation and support the research and development of new radiopharmaceuticals.
  • Proportionate Risk Management: Advocate for risk management strategies tailored specifically to radiopharmaceuticals, avoiding one-size-fits-all models.
  • Flexible Clinical Trials Frameworks: Advocate for flexible clinical trial requirements that consider the specific challenges of radiopharmaceutical development, such as small patient populations and the need for specialized imaging and diagnostic techniques.

Key EU Initiatives

  • European Medicines Agency (EMA) Guidelines: Collaborate with the EMA to refine Guidelines governing the authorisation and monitoring of radiopharmaceuticals, ensuring they are appropriately tailored.
  • EU Pharmaceutical Legislation (Directive 2001/83/EC and Regulation (EC) No 726/2004): Engage with these key legislative frameworks to ensure they adequately address the unique requirements of radiopharmaceuticals.
  • Basic Safety Standards Directive (Council Directive 2013/59/Euratom): Collaborate with the European Commission for better implementation of the Basic Safety Standards.
  • Clinical Trials Regulation (EU) No 536/2014 : Advocate for the inclusion of specific provisions for radiopharmaceuticals in clinical trial regulations.

EANM Actions & Initiatives

  • Regulatory Advocacy: Actively participate in relevant consultations and working groups to influence regulatory policies, ensuring that the unique needs of radiopharmaceuticals are considered.
  • Policy Recommendations: Develop and submit detailed policy recommendations to European and national regulatory bodies, promoting flexible and efficient regulatory approaches.
  • Stakeholder Engagement: Collaborate with a wide range of stakeholders, including policymakers, industry leaders, and healthcare professionals, to build consensus on optimal regulatory pathways.
By focusing on these advocacy priorities, the EANM aims to create a more flexible and responsive regulatory framework for radiopharmaceuticals in Europe, fostering innovation and ensuring that patients have timely access to advanced diagnostic and therapeutic options.